News

Article

Dalpiciclib Plus Endocrine Therapy Prolonged Invasive Disease-Free Survival in HR+/HER2– Breast Cancer

Key Takeaways

  • Dalpiciclib combined with ET significantly improved progression-free survival in HR+/HER2– advanced breast cancer in the DAWNA-A trial.
  • The trial demonstrated superior iDFS with dalpiciclib plus ET compared to placebo, with consistent benefits across subgroups.
SHOW MORE

Dalpiciclib combined with endocrine therapy significantly enhances progression-free survival in HR+/HER2– breast cancer, as shown in the DAWNA-A trial.

Dalpiciclib (SHR6390; Jiangsu Hengrui Medicine Co) in combination with endocrine therapy (ET) significantly improved progression-free survival (PFS) in first- and later-line settings for hormone receptor-positive (HR+)/HER2– advanced breast cancer. These data, from a first interim analysis of the phase 3 DAWNA-A trial (NCT03927456), were presented at the 2025 American Society of Clinical Oncology Annual Meeting in Chicago.1

Breast cancer cells | Image Credit: © sknab - stock.adobe.com

Breast cancer cells | Image Credit: © sknab - stock.adobe.com

Dalpiciclib is an oral CDK4/6 inhibitor that targets overexpressed CDK4/6 proteins to interrupt cancer cell proliferation. It is approved in China by the National Medical Products Administration in combination with fulvestrant (Falsodex; AstraZeneca) for the treatment of relapsed/progressed HR+/HER2- advanced breast cancer. As of 2025, it’s not approved by the FDA.2,3

DAWNA-A is a randomized, double-blind, phase 3 study evaluating dalpiciclib plus ET as adjuvant therapy in 5274 patients (ages 18 to 75) with stage 2 to 3 HR+/HER2– breast cancer and pathologically confirmed ipsilateral axillary lymph node involvement. They were randomized 1:1 to receive either daily dalpiciclib at a dosage of 125 mg (3 weeks on/1 week off for 2 years) plus ET (letrozole 2.5 mg; anastrozole 1 mg; tamoxifen 10 mg; toremifene 60 mg daily for 5 years; n = 2640) or placebo + ET (n = 2634). The trial’s primary end point was invasive disease-free survival (iDFS), with secondary end points including DFS, distant DFS (DDFS), overall survival (OS), and safety.4

Pre- and perimenopausal patients received LHRH agonists, with use in perimenopausal patients determined at the investigator’s discretion. Stratification factors included menopausal status (pre/perimenopausal vs postmenopausal), clinical stage (2 vs 3), number of involved lymph nodes (<4 vs ≥4), and receipt of adjuvant chemotherapy (yes vs no).4

At the median follow-up of 20.3 months, patients treated with dalpiciclib in combination with ET achieved superior iDFS compared with the placebo group (HR 0.56, 95% CI 0.43–0.71; 1-sided P < .0001), and these benefits were consistent across subgroups. Additionally, dalpiciclib plus ET was preferred over placebo plus ET by DFS and distant DFS.4

“The phase III DAWNA-A met its primary end point at the first internal analysis, with significant iDFS benefits with dalpiciclib plus [ET] versus placebo plus [ET],” said Zhi-Ming Shao, PhD, Fudan University Shanghai Cancer Center, in their presentation.4

The safety profile was favorable, with no deaths due to treatment-related adverse events (TRAEs). Treatment-related adverse events (TRAEs) occurred in 3.7% of patients in the dalpiciclib arm and 1.5% in the placebo arm, leading to treatment discontinuation in 2.1% and 0.8% of patients, respectively.4

“Our data supports dalpiciclib plus [ET] as a neoadjuvant treatment option for [HR+/HER2–] early breast cancer, especially in Chinese populations,” concluded Shao.4

REFERENCES
1. A study of SHR6390 in combination with fulvestrant in patients with HR positive and HER2 negative advanced breast cancer. Updated June 3, 2021. Accessed July 11, 2025. https://clinicaltrials.gov/study/NCT03927456
2. New CDK4/6 Inhibitor offers benefits for advanced-stage, hormone receptor-positive, HER2-negative breast cancer. Breastcancer.org. November 16, 2022. Accessed July 11, 2025. https://www.breastcancer.org/research-news/new-cdk46-inhibitor-offers-benefits-for-advanced-stage-hormone-receptor-positive-her2-negative-breast-cancer
3. NMPA approves AiRuiKang® (dalpiciclib) in combination with fulvestrant for the treatment of relapsed/progressed HR+/HER2- advanced breast cancer. Hengrui. January 3, 2021. Accessed July 11, 2025. https://www.hengrui.com/en/media/detail-149.html
4. Shao ZM, Hao J, Wang S, et al. Dalpiciclib (Dalp) plus endocrine therapy (ET) as adjuvant treatment for HR+/HER2– early breast cancer (BC): The randomized, phase 3, DAWNA-A trial. 2025 ASCO Annual Meeting. Chicago, IL. Abstract 515

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Pharmacist and doctor -- Image credit: ake1150 | stock.adobe.com